Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy

Journal of Child Neurology

Volumn 21, Issue 5, 2006, Pages 411-414

  Tekgul, Hasan ^a   Serdaroglu, Gul ^a   Huseyinov, Afig ^a   Gökben, Sarenur ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTICONVULSIVE AGENT; BIOCHEMICAL MARKER; CALCITONIN; CALCIUM; CARBAMAZEPINE; CREATININE; OSTEOCALCIN; PARATHYROID HORMONE; PHENOBARBITAL; PHOSPHORUS; VALPROIC ACID; VITAMIN D;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; BONE DENSITY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DRUG ERUPTION; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEBRILE CONVULSION; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; HYPERPARATHYROIDISM; IMMUNORADIOMETRIC ASSAY; LONG TERM CARE; LONG TERM EXPOSURE; LONGITUDINAL STUDY; LUMBAR SPINE; MALE; MONOTHERAPY; MULTIPLE REGRESSION; OSSIFICATION; OSTEOPENIA; OUTPATIENT CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

ADOLESCENT; AMBULATORY CARE; ANTICONVULSANTS; BIOLOGICAL MARKERS; BONE DENSITY; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; OSTEOGENESIS; VITAMIN D;

EID: 33745939485     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.2310/7010.2006.00066     Document Type: Article

References (22)

1. Barden HS, Mazess RB, Chesney RW, et al: Bone status of children receiving anticonvulsant therapy. Metab Bone Dis Ret at Res 1982; 4:43-47.
2. Matsuda I, Higashi A, Inotsume N: Physiologic and metabolic aspects of anticonvulsants. Pediatr Clin North Am 1989;36: 1099-1111.
3. Nishiyama S, Kuwahara I, Matsuda I: Decreased bone density in severely handicapped children and adults, with reference to the influence of limited mobility and anticonvulsant medication. Eur J Pediatr 1986;144:457-463.
4. Timperlake RW, Cook SD, Thomas KA, et al: Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population. J Pediatr Orthop 1988;8:467-470.
5. Sheth RD, Wesolowski CA, Jacob JC, et al: Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-262.
6. Valimaki MJ, Tiihonen M, Laitinen K, et al: Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994;9:631-637.
7. Verrotti A, Greco R, Latini G, et al: Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-1492.
8. Telci A, Cakatay U, Kurt BB, et al: Changes in bone turnover and deoxypyridinoline levels in epileptic patients. Clin Chem Lab Med 2000;38:47-50.
9. Feldkamp J, Becker A, Witte OW, et al: Long-term anticonvulsant therapy leads to low bone mineral density evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 2000;108:37-43.
10. Baer MT, Kozlowski BW, Blyler EM, et al: Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am J Clin Nutr 1997;65:1042-1051.
11. Jekovec-Vrhovsek M, Kocijancic A, Prezelj J: Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full-time care. Dev Med Child Neurol 2000;42:403-405.
12. Pavlakis SG, Chusid RL, Roye DP, Nordli DR: Valproate therapy: Predisposition to bone fracture? Pediatr Neurol 1998;19:143-144.
13. Chung S, Ahn C: Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994;16:382-385.
14. Akin R, Okutan V, Sarici U, et al: Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 1998;19:129-131.
15. Erbayat AE, Serdaroglu A, Tumer L, et al: Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000;13:933-939.
16. Kafali G, Erselcan T, Tanzer F: Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr 1999;38:93-98.
17. Jubitz W, Haussler MR, McCain TA, Tolman KG: Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab 1977;44:617-621.
18. Tjellesen L, Gotfredsen A, Christiansen C: Effect of vitamin D2 and D3 on bone-mineral content in carbamazepine-treated epileptic patients. Acta Neurol Scand 1983;68:424-428.
19. Ala-Houhala M, Korpela R, Koivikko M, et al: Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children. Neuropediatrics 1986;17:212-216.
20. Tsukahara H, Kimura K, Todoroki Y, et al: Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002;44:247-253.
21. Goksen D, Coker M, Darcan S: Bone mineral measurements in prepubertal Turkish children, abstract. Pediatr Res 2001;49 (Suppl):28A.
22. Takeshita N, Seino Y, Ishida H, et al: Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif Tissue Int 1989;44:80-85.